HTT and Huntington disease: The use of β-1,3-D-glucan-encapsulated anti-HTT siRNA particles (GeRPs) in prior studies involving monocyte-derived macrophages from Huntington’s disease patients showed apparent effects on cytokine release following stimulation whether it be the mutant or the wild-type HTT allele that was specifically targeted49, with some indication of a similar effect in the control cells from healthy individuals46,49.